Instil Bio, Inc.
TIL evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $50.1M
- Lead Asset:
- axn-2510 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for TIL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TIL
Instil Bio, Inc. (TIL) is a clinical-stage biotechnology company focused on identifying and advancing innovative therapeutics, currently evaluating potential acquisitions and in-licensing opportunities after discontinuing its former lead candidate AXN-2510.
Key risk: Lead candidate discontinued
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$50.1M
Cash Runway
—
Lead Asset
axn-2510 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials for Instil Bio, Inc..
Instil Bio, Inc. (TIL) is a clinical-stage biotechnology company focused on identifying and advancing innovative therapeutics, currently evaluating potential acquisitions and in-licensing opportunities after discontinuing its former lead candidate AXN-2510.
- Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported cash & equivalents of $5.5M and net income of -$4.3M [latest reported financials].
- The company's pipeline includes ITIL-306, a Phase 1 genetically modified TIL targeting folate receptor alpha (FRα) for epithelial ovarian cancer [pipeline].
- In January 2026, Instil Bio announced the discontinuation of AXN-2510, its former lead product candidate [sec_mda · as of 2026-08-13].
- Instil Bio is actively seeking to in-license or acquire and develop additional novel therapeutic candidates [sec_mda · as of 2026-08-13].
What works
- Instil Bio has a pipeline candidate, ITIL-306, in Phase 1 for epithelial ovarian cancer, which uses a genetically modified TIL platform targeting FRα [pipeline].
- The company maintains a cash position of approximately $69.9 million as of June 30, 2026, expected to fund current operations [news · published 2026-08-13].
- Instil Bio is actively evaluating potential acquisitions and in-licensing opportunities to access promising novel therapeutic candidates [news · published 2026-08-13].
What to weigh
- Instil Bio discontinued development of AXN-2510, its former lead product candidate, in January 2026 [sec_mda · as of 2026-08-13].
- The company reported a net loss of $4.3M as of June 30, 2026 [latest reported financials].
- Instil Bio's future operating expenditures are uncertain, depending on factors such as the extent of acquisitions, clinical development costs, and regulatory outcomes [sec_mda · as of 2026-05-15].
- The company has no approved products and is dependent on in-licensing or acquiring new candidates to build its pipeline [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Instil Bio discontinued its former lead product candidate AXN-2510 in January 2026.
“In January 2026, we announced that our wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of AXN-2510, our former lead product candidate.”
SEC MD&A · August 13, 2026
Instil Bio is evaluating potential acquisitions and in-licensing opportunities.
“Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.”
News · August 13, 2026
Instil Bio's pipeline includes ITIL-306, a Phase 1 candidate for epithelial ovarian cancer.
“Pipeline Candidate: itil-306 Indication: Epithelial Ovarian Cancer Phase: Phase 1 Mechanism of Action: Genetically modified TIL targeting folate receptor alpha (FRα) using CoStAR platform”
Instil Bio reported cash of approximately $69.9 million as of June 30, 2026.
“Cash position of approximately $69.9 million as of June 30, 2026”
News · August 13, 2026
Risks & what to watch (4)›
Key risks
- Lead candidate discontinued — Instil Bio discontinued AXN-2510, its former lead product candidate, in January 2026 [sec_mda · as of 2026-08-13].
- No approved products — The company has no marketed products and relies on in-licensing or acquiring new candidates [sec_mda · as of 2026-08-13].
- Net loss reported — As of June 30, 2026, net income was -$4.3M [latest reported financials].
- Uncertain funding needs — Future expenditures depend on acquisition scope, clinical progress, and regulatory outcomes [sec_mda · as of 2026-05-15].
What to watch
- Instil Bio's progress in evaluating potential acquisitions and in-licensing opportunities to replace its discontinued lead candidate [news · published 2026-08-13].
- Clinical development of ITIL-306 in Phase 1 for epithelial ovarian cancer [pipeline].
- Cash runway and financial sustainability, given cash of $69.9M as of June 30, 2026 and ongoing net losses [news · published 2026-08-13] [latest reported financials].
- Any updates on the company's ability to secure new therapeutic candidates and advance them through clinical trials [sec_mda · as of 2026-08-13].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Instil Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Instil Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.84 · 0% dilution
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 10.3%
- Days to cover
- 15.6
- Shares short
- 414,920
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TIL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Instil Bio, Inc.?
Instil Bio, Inc. (TIL) is a clinical-stage biotechnology company focused on identifying and advancing innovative therapeutics, currently evaluating potential acquisitions and in-licensing opportunities after discontinuing its former lead candidate AXN-2510.
What is Instil Bio, Inc.'s lead drug candidate?
Instil Bio, Inc.'s most advanced tracked candidate is axn-2510 (Phase 1) for Solid Tumor, Adult.
Who is the CEO of Instil Bio, Inc.?
Mr. Bronson Crouch is the chief executive officer of Instil Bio, Inc. (TIL).
Where is Instil Bio, Inc. headquartered?
Instil Bio, Inc. (TIL) is headquartered in Dallas, TX, United States.
What therapeutic areas does Instil Bio, Inc. focus on?
Instil Bio, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.